Stock Analysis·← Pickers

IART

Integra LifeSciences Holdings Corporation

Integra LifeSciences Holdings Corporation (IART) is currently in an uptrend, trading above both the 50-day and 200-day moving averages. RSI is at 62.2, with 3/3 trend checks passing.

Price
$18.78
2026-07-16
Trend score
3/3
Uptrend
RSI (14)
62.2
Neutral
Price above MA50Price above MA200MA50 above MA200
Change stock
Search another ticker to view its stock analysis page.
Chart View

IART with MA50 and MA200

18.7916.3213.8411.378.9007/3110/2401/2204/1707/15
IART2025-07-312026-07-15
PriceMA50MA200
Technical Indicators

Key levels & signals

MA50
$16.42+14.35% vs price
MA200
$13.05+43.87% vs price
RSI (14)
62.2Neutral zone
MACD Signal
BearishMomentum below signal
Macro Support
Not identifiedNo repeated weekly support zone found
Support Quality
Volume data unavailable
Chart Summary
Trend summary for IART

Integra LifeSciences Holdings Corporation (IART) is still trading in a constructive trend overall. The latest available price is $18.78, and 3 of 3 core trend checks are currently passing. Price is trading above the 50-day moving average by 14.3% and above the 200-day moving average by 43.9%.

Momentum and stretch context

IART currently has an RSI reading of 62.2, which leans mildly positive without looking too stretched. In other words, momentum is supportive, but not yet extreme enough to dominate the entire chart read.

What traders may watch next

For traders reviewing IART next, the key question is whether the trend still looks healthy or whether price has started to outrun itself. A strong uptrend can stay strong, but entries often become more difficult when price is already extended, so many traders will watch for pullbacks, support reactions, or fresh bases rather than chasing strength blindly.

Company profile

About Integra LifeSciences Holdings Corporation

Integra LifeSciences Holdings Corporation is a medical technology company focused on the creation, production, and global distribution of advanced surgical implants and instruments. These products are utilized across various medical fields, including neurosurgery, limb reconstruction, and general surgical procedures. The company operates through two primary business segments: Codman Specialty Surgical and Tissue Technologies. The Codman Specialty Surgical division offers a comprehensive range of neurosurgical and neuro-critical care products. This includes specialized equipment for tissue ablation, dural repair solutions, cerebral spinal fluid management systems, intracranial monitoring tools, and cranial stabilization devices. Additionally, this segment provides surgical headlamps, various instrumentation, and supports these offerings with asset management software, technical assistance, and after-market services. Integra also supplies an extensive catalog of approximately 40,000 surgical instrument designs, along with a wide selection of surgical and lighting products. Its clientele spans hospitals, surgical centers, and extends to dental, podiatry, and veterinary practices. The Tissue Technologies segment specializes in innovative regenerative technology products for the treatment of both acute and chronic wounds. It further provides surgical tissue repair solutions for a multitude of applications, such as hernia repair, peripheral nerve protection and regeneration, and tendon reconstruction. This encompasses a broad array of offerings for skin and wound repair, plastic and reconstructive surgery products, bone grafting materials, and specialized nerve and tendon repair products. Integra LifeSciences distributes its diverse product portfolio internationally, reaching markets throughout the United States, Europe, Asia Pacific, and other global regions. Distribution is managed directly through its dedicated sales forces and various other channels, serving a wide array of healthcare entities including hospitals, integrated health networks, group purchasing organizations, individual clinicians, surgery centers, and other healthcare providers. Founded in 1989, Integra LifeSciences Holdings Corporation is headquartered in Princeton, New Jersey.

Sector
Healthcare
Industry
Medical - Devices
CEO
Stuart Essig
Employees
4,427
Market cap
$1.46B
Beta
1.22
52-week range
$8.70 – $19.13
Dividend
No
Exchange
NASDAQ
Country
US
IPO date
16 Aug 1995
ISIN
US4579852082
CUSIP
457985208
Company profile data from Financial Modeling Prep. IART listed on NASDAQ.
Learn More

Learn the indicators behind this page

Explore More

More stock opportunities

FAQ

Common questions about IART

Is this page a buy or sell recommendation?

No. This page is designed to help you review chart structure, momentum and technical context more quickly, but it is not personal financial advice.

Why can a stock look bullish and overbought at the same time?

Strong trending stocks can still become stretched in the short term. That is why trend traders and dip buyers can read the same chart differently.

What should I do next after reading this page?

Open the full dashboard, review the chart in more detail, compare indicators, and decide whether the setup still makes sense within your own process.